86788-98-9

Upstream product

• 33821-58-8 6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid 
• 67367-33-3 4-hydroxy-6-methylnicotinic acid 

Downstream Products

• 1569643-14-6 1-ethyl-6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 4-methanesulfonyl-benzylamide 
• 1569649-33-7 6-methyl-4-oxo-5-(3-trifluoromethyl-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid 4-methanesulfonyl-benzylamide 
• 880261-50-7 methyl 4-(benzyloxy)-5-{((4-fluorobenzyl)carbanoyl)}-3-methoxypyridine-2-carboxylate 
• 880261-49-4 4-benzyloxy-N-(4-fluorobenzyl)-6-formyl-5-methoxynicotineamide 
• 880261-48-3 4-benzyloxy-N-[(4-fluorobenzyl)]-6-hydroxymethyl-5-methoxynicotinamide 
• 880261-47-2 4-benzyloxy-N-(4-fluorobenzyl)-5-methoxy-6-methylnicotineamide-N-oxide 
• 880261-46-1 4-benzyloxy-N-(4-fluorobenzyl)-5-methoxy-6-methylnicotinamide 
• 880261-45-0 N-(4-fluorobenzyl)-4-hydroxy-5-methoxy-6-methylnicotinamide 
• 1400003-23-7 C₂₄H₂₄FN₃O₄ 
• 1400003-21-5 C₂₃H₂₂FN₃O₄ 
• 880261-53-0 4-Benzyloxy-3-methoxy-pyridine-2,5-dicarboxylic acid 2-amide 5-(4-fluoro-benzylamide) 
• 880261-52-9 4-benzyloxy-5-(4-fluorobenzylcarbamoyl)-3-methoxypyridine-2-carboxylic acid 
• 880261-51-8 methyl 5-{((4-fluorobenzyl)carbamoyl)}-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 880261-44-9 5-bromo-N-(4-fluorobenzyl)-4-hydroxy-6-methylnicotinamide 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS OF USE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmona

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

P01-2864-ff 32/132 -132- ABSTRACT This invention relates to substituted 4-pyridones of formula R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1 and their use as inhibitors ofneutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore

Our group has focused on expanding the scope of a two-metal binding pharmacophore concept to explore HIV-1 integrase inhibitors through medicinal chemistry efforts to design novel scaffolds which allow for improvement of pharmacokinetic (PK) and resistanc

INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is -O-, -N(R3)-, -S-, -S(O)- or -S(O)2-; R2 is a C1-4 alkyl group or -CF3; and R1, R3, R4 and p are as defined herein; wherein the compounds are useful as kinase inhibitors. Also disclosed are pharmaceutical compositions containing, and intermediate compounds and methods for making the compounds of formula (I) and their pharmaceutically acceptable salts; and methods of using the foregoing to treat inflammatory and autoimmune diseases such as asthma, colitis, multiple sclerosis, psoriasis, arthritis, rheumatoid arthritis, inflammatory bowel disease, and joint inflammation.

5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS

Described herein are compounds of formula I: wherein G is and pharmaceutically acceptable salts thereof, wherein J, X, R1, R2, R11, R12' and p are as defined herein. Also provided herein are methods of making the compounds of formula I, and methods of using these compounds for inhibiting or treating a pathological condition or disorder linked to or mediated by a protein kinase in a mammal.

CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

An object of the present invention provides a novel compound having the anti-viral activity, particularly, the HIV integrase inhibitory activity, and a drug containing the same, particularly, an anti-HIV drug. There is provided a compound represented by t

Pyrazolo-pyridine derivatives as ligands for GABA receptors

Pyrazolo[4,3-c]pyridin-3-one derivatives substituted at the 2-position by an optionally substituted aryl or heteroaryl moiety, and having pendant substituents at the 7-position and optionally also at the 6-position, are selective ligands for GABAAreceptors, particularly having high affinity for the α2 and/or α3 subunit, and are useful in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.